Curative treatment of peritoneal carcinomatosis of colorectal origin

摘要

Up to 8% of all patients with colorectal cancer have peritoneal carcinomatosis (PC) as the only site of disease at some point in time. Traditional treatment by limited palliative surgery and systemic chemotherapy has poor results with few patients surviving longer than 3 years. Complete cytoreductive surgery combined with Hyperthermic Intra Peritoneal Chemotherapy (HIPEC), using Mitomycin C, followed by adjuvant chemotherapy has been extensively tested. Both in Phase II and in randomised phase III trials this combination therapy has shown superior results, with a median survival of 2 years and a 5-year disease-free survival of 20-25%.